IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma
Status:
Not yet recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
This is an open label, multi-cohort, and multi-center phase II study, which evaluates the
clinical activity and safety of IPH4102 in Sezary Syndrome and Mycosis fungoides as single
agent, and in patients with peripheral T-cell lymphoma in combination with gemcitabine and
oxaliplatin chemotherapy (GEMOX)